Cartesian Therapeutics
RNAC

Cartesian Therapeutics (RNAC) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
HC Wainwright & Co.MaintainedBuy$25.00Sep 30, 2026
NeedhamMaintainedBuy$40.00Sep 29, 2026
WedbushMaintainedOutperform$38.00Aug 18, 2026
WedbushMaintainedOutperform$38.00Jun 10, 2026
BTIGMaintainedBuy$44.00Jun 9, 2026
NeedhamMaintainedBuy$40.00Jun 9, 2026
WedbushMaintainedOutperform$38.00May 27, 2026
NeedhamMaintainedBuy$40.00 from $42.00May 26, 2026
HC Wainwright & Co.MaintainedBuy$25.00 from $30.00May 12, 2026
WedbushMaintainedOutperform$38.00May 1, 2026
WedbushMaintainedOutperform$38.00Mar 10, 2026
NeedhamMaintainedBuy$42.00Mar 9, 2026
Cantor FitzgeraldUpgradedNeutral → Overweight$16.00Mar 9, 2026
NeedhamMaintainedBuy$42.00 from $40.00Jan 9, 2026
HC Wainwright & Co.MaintainedBuy$30.00 from $40.00Nov 19, 2025
BTIGMaintainedBuy$44.00 from $42.00Nov 14, 2025
WedbushInitiated CoverageOutperform$38.00Jul 9, 2025
NeedhamMaintainedBuy$40.00 from $41.00May 8, 2025
HC Wainwright & Co.MaintainedBuy$40.00Apr 9, 2025
NeedhamMaintainedBuy$41.00Apr 9, 2025

Frequently asked questions

  • What is the latest analyst rating on RNAC?

    On Sep 30, 2026, HC Wainwright & Co. maintained Cartesian Therapeutics at Buy with a price target of $25.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.